- Price is above Fair Value, showing premium demand versus the model.
AJ91
GER
Week ended 07 Aug 2026
Weekly Investor Report
DocCheck AG · Healthcare · Health Information Services
Latest close
11.40 EUR
-1.7%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -4.6% below the Trend Line and sits at 29.5% of its 52-week range. The latest completed week returned -1.7%, after a -5.0% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is inexpensive relative to peers. The latest news-sentiment score is 50/100.
Setup score
30
out of 100
Latest Close
11.40 EUR
7 Aug 2026
1W Return
-1.7%
latest completed week
4W Return
-5.0%
short-term follow-through
12W Return
-18.0%
quarterly tape
Trend Breadth
55.8%
29 of 52 weeks active
Volume Ratio
1.2x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Activity pressure is negative, which weakens the current setup.
- Next-week expectancy is negative at 44.95% based on similar historical setup states.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-1.7%
Latest completed week; four-week move -5.0%.
Indicator stack
31/22
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 44.95%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
50/100
1 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -4.6% below the Trend Line and sits at 29.5% of its 52-week range. The latest completed week returned -1.7%, after a -5.0% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.2x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.5212-week average 0.64
12-week confirmation
Trend active6/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure5/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership4/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.52Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers11 reversal markers
No recent accumulation markers. 1 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -5.0% over four weeks, -18.0% over 12 weeks, and 3.4% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year29
Trend breadth55.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.79Latest activity-pressure read.
Pressure change-165.4%Four-week change in activity pressure.
Leadership-9.57Latest relative-leadership reading.
RS change-3386.2%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is inexpensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 31 Dec 2025
Field coverage 91%
Model confidence 72%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength93/100Blend of value, momentum, and quality. Underlying universe rank 8; rank 1 is best.
Value89/100Relative valuation strength. Underlying universe rank 12; rank 1 is best.
Quality83/100Profitability and accounting quality. Underlying universe rank 18; rank 1 is best.
Momentum41/100Medium-term price momentum. Underlying universe rank 60; rank 1 is best.
Growth35/100Revenue and earnings growth. Underlying universe rank 66; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework96/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 10.8x Price divided by trailing earnings.
- Price / sales
- 1.0x Market value relative to trailing revenue.
- EV / EBITDA
- 4.1x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 4.7% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 67.4% Gross profit retained from each unit of revenue.
- Operating margin
- 15.9% Operating profit retained from revenue.
- Free-cash-flow margin
- 4.0% Free cash flow generated from revenue.
- Return on invested capital
- 21.0% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 2.8% Latest one-year revenue growth.
- EPS growth
- 1.0% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -65.6% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 9/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 8.8% Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 8.8% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -0.9x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 1 relevant articles.
0 positive · 1 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-22.6%Distance below the 52-week high.
13-week volatility4.2%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher8 of 2615 weeks finished lower.
Best week+13.2%Week of 8 May.
Worst week-12.0%Week of 22 May.
Latest week-1.7%Week of 7 Aug.
Shape of recent returns
Strong gains5
Modest gains3
Flat weeks3
Modest losses12
Sharp losses3
Recent vol4.2%13-week weekly-return volatility.
Base vol4.5%52-week weekly-return volatility.
Up/down split19/25Count of positive and negative weeks in the 52-week window.
Average skew4.5% / -3.1%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorDE Healthcare
4-week rank60 / 78
Group average1.4%
Trend breadth39.7%
Trend39.7%active weekly trend signals
MD69.2%positive activity pressure
RS34.6%positive relative leadership
Four-week leaders
IndustryDE Health Information Services
4-week rank2 / 2
Group average-3.7%
Trend breadth0.0%
Trend0.0%active weekly trend signals
MD50.0%positive activity pressure
RS0.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape30/100
Trend, activity pressure, participation, and risk combine to a 30/100 tape read.
Indicator analysis44/100Latest 12-week confirmation: trend 6/12, activity pressure 5/12, relative leadership 4/12.
Activity pressure 0.52; 1 reversal markers Next-Week ExpectancyNegative 44.95%Next-week expectancy is negative with a 44.95% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors77/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 61; Small Cap Core rank 12 SVQF96/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 15.0 of 375 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 1 relevant articles.
Historical AJ91.F stock prices (quote) - DocCheck AG Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 11.40 EUR | -1.7% | 11.95 EUR | 9.21 EUR | -0.79 | -9.57 | 3.7K | Off |
| 31 Jul 2026 | 11.60 EUR | 0.0% | 11.97 EUR | 9.19 EUR | -0.59 | -5.59 | 2.6K | Off |
| 24 Jul 2026 | 11.60 EUR | -2.5% | 11.97 EUR | 9.18 EUR | -0.47 | -3.70 | 3.8K | Off |
| 17 Jul 2026 | 11.90 EUR | -0.8% | 11.93 EUR | 9.16 EUR | -0.37 | -0.21 | 1.3K | Off |
| 10 Jul 2026 | 12.00 EUR | 3.4% | 11.88 EUR | 9.14 EUR | -0.30 | -0.27 | 669 | Off |
| 3 Jul 2026 | 11.60 EUR | 0.9% | 11.82 EUR | 9.12 EUR | -0.23 | -6.26 | 24 | Off |
| 26 Jun 2026 | 11.50 EUR | -1.7% | 11.79 EUR | 9.11 EUR | -0.07 | -3.03 | 729 | On |
| 19 Jun 2026 | 11.70 EUR | -5.6% | 11.76 EUR | 9.09 EUR | 0.25 | -2.53 | 103 | On |
| 12 Jun 2026 | 12.40 EUR | -2.4% | 11.72 EUR | 9.08 EUR | 0.39 | 4.70 | 208 | On |
| 5 Jun 2026 | 12.70 EUR | -2.3% | 11.66 EUR | 9.06 EUR | 0.58 | 6.87 | 1 | On |
| 29 May 2026 | 13.00 EUR | 6.3% | 11.62 EUR | 9.04 EUR | 0.85 | 8.12 | 16.7K | On |
| 22 May 2026 | 12.23 EUR | -12.0% | 11.57 EUR | 9.03 EUR | 0.68 | 2.86 | 8.7K | On |
| 15 May 2026 | 13.90 EUR | -2.6% | 11.54 EUR | 9.02 EUR | 0.49 | 21.68 | 2.1K | On |
| 8 May 2026 | 14.27 EUR | 13.2% | 11.48 EUR | 8.99 EUR | 0.12 | 23.68 | 17.4K | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.